Experienced Animal Health Executive to lead Commercialization and Business Development

STOCKHOLM and NEW YORK, September 16, 2015 /PRNewswire/ --

Premune, a research and development stage animal health company focused on new therapeutics for companion animals, today announced the appointment of Ed Torr as Head of Business Development and Commercial Operations, effective September 7, 2015. Mr. Torr, who will be based in the UK, will oversee Premune's commercialization and business development efforts as the company prepares for its initial product launches.

Ed brings more than 30 years of experience in animal health with senior leadership roles in some of the most prominent animal health companies in Europe including ICI, Coopers Animal Health, Alfa Laval Agri and Dechra Pharmaceuticals PLC. He was an executive director of Dechra Pharmaceuticals PLC from 2000-14 during which time he had responsibility for business development, manufacturing and product development, Dechra Veterinary Products Europe and geographical expansion.

"We are very excited to welcome Ed to the Premune team," stated Premune CEO and co-founder Viktor Karlsson. "His impressive track record in driving commercial success and expanding animal health portfolios across several geographies fits perfectly with our plans to transition from being a pure R&D player to being a company that is a commercial player with a strong R&D portfolio."

Ed Torr remarked, "I am delighted to be joining a team with entrepreneurial flair and a clear strategy to build a presence in the global veterinary market."

Ed joins Premune in their efforts to broaden their product portfolio with strategic in-licensing opportunities and proprietary innovations.

About Premune

Premune is a research and development stage animal health company focused on the development and commercialization of novel therapeutics for the treatment and prevention of some of the most common conditions affecting companion animals. The Company's pipeline of compounds under development seeks to target indications such as allergies and inflammatory diseases that are highly prevalent in cats and dogs. Premune's current product candidates are the result of decades of collective research in bacteriology and immunology at the University of Gothenburg, one of Sweden's leading academic institutions. Premune's pipeline consists of compounds in various stages of clinical development. The Company is continuously seeking to expand its therapeutic portfolio through a combination of in-house research and development projects in conjunction with its academic partners and the strategic in-licensing of additional product candidates. The Company's in-licensing strategy is to identify therapeutic entities in development for humans that exhibit potential efficacy in companion animals as well. Premune´s goal is to improve the quality of life for companion animals worldwide by translating leading human research to pets. For more information, visit http://www.premune.com.

SOURCE Premune

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…